boi568
3 minutes ago
Investor understands that Anavex is not going to be applying for an accelerated decision (which is why "surrogate endpoints," i.e., biomarkers, are not relevant), but he nonetheless posted the new FDA draft guidance regarding the need for an existing second trial using such biomarkers in an effort t